Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency Syndrome
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
This PHASE1 trial investigates Cytomegalovirus Retinitis and HIV Infections and is currently completed. National Institute of Allergy and Infectious Diseases (NIAID) leads this study, which shows 6 recorded versions since 2026 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Allergy and Infectious Diseases (NIAID)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Los Angeles, United States
- • New York, United States
- • San Francisco, United States